| 中文名称 | 泮托拉唑钠水合物 |
| 英文名称 | PantoprazoleSodiumSesquihydrate |
| CAS号 | 164579-32-2 |
| 分子式 | C16H18F2N3NaO5S |
| 分子量 | 425.38 |
| EINECS号 | 1312995-182-4 |
| 溶解度 | 易溶于水和乙醇(96%),几乎不溶于己烷。 |
| 形态 | 固体 |
| 颜色 | 白色至米白色 |
| 危险品标志 | Xn |
| 危险类别码 | 22 |
| WGK Germany | nwg |
| 海关编码 | 2933399090 |
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 1-10000 μM) leads to concentration-dependent increases in endosomal pH in EMT-6 and MCF7 cells.
Pantoprazole sodium hydrate can block exosome release. Pantoprazole sodium hydrate inhibits the activity of V-H
+
-ATPase and impaires the ability of tumour cells (melanomas, adenocarcinomas, and lymphoma cell lines) to acidify the extracellular medium
Pantoprazole sodium hydrate (BY1023 sodium hydrate; 200 mg/kg; IP; once a week for 3 weeks) significantly increases tumor growth delay of MCF-7 xenografts combined with Doxorubicin.
Pantoprazole sodium hydrate (0.3-3 mg/kg, p.o.) dose-dependently decreases both basal acid secretion in pylorus-ligated rats and the stimulated acid secretion induced by mepirizole in acute fistula rats.
| Animal Model: | Mice bearing MCF-7 or A431 xenografts |
| Dosage: | 200 mg/kg |
| Administration: | IP; once a week for 3 weeks; alone or 2 hours before Doxorubicin (6 mg/kg i.v.) |
| Result: |
Showed even greater growth delay of MCF-7 xenografts with Doxorubicin compared with the single-dose combination.
Significantly increased tumor growth delay with a single dose with Doxorubicin. There is no effect on growth delay alone. |